Plain-English translation of NCT05690048 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a (FMT)—a transplant of healthy gut bacteria—can help make atezolizumab and bevacizumab work better for people with hepatocellular carcinoma (liver cancer). Half the participants will receive the gut bacteria transplant along with the standard medication, while the other half will receive placebo capsules along with the same medication. Researchers believe that the right balance of gut bacteria might help the immune system respond better to this treatment.
Some patients with liver cancer don't respond well to this immunotherapy medication, and doctors are looking for ways to improve its effectiveness. Recent research suggests that the bacteria living in our gut play an important role in how well immunotherapy works, which is why researchers want to test whether transplanting healthy bacteria might help.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic multiple times over several months. Before treatment starts, you'll have a sigmoidoscopy (a scope inserted into your lower bowel to take samples). You'll take an antibiotic for a few days, then receive either the gut bacteria capsules or placebo capsules on day 0 and day 21. Throughout the study, you'll receive the standard immunotherapy medication every 3 weeks. You'll have imaging scans and another sigmoidoscopy around week 6 to see how you're responding. Researchers will monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Germany